BCL6 is a regulator of SOCS2, so less BCL6 leads to less SOCS2. At normal levels, this allows BCL6 to control how much SOCS2 is expressed, and therefore, how much IGF1 is made.

In a recent study, scientists have linked the protein BCL6 to the maintenance of muscle mass and further suggested that BCL6-boosting therapeutics could help GLP-1 users retain muscle while losing ...